Adicet Bio Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Adicet Bio Announces FDA Clearance Of IND Amendment To Evaluate ADI-001 In Idiopathic Inflammatory Myopathy And Stiff Person Syndrome
Adicet Bio Inc reports results for the quarter ended in January - Earnings Summary
Brief: Adicet Bio Q2 Basic EPS USD -0.33
Adicet Bio Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Adicet Bio Receives FDA Fast Track Designation For ADI-270 In Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-270
Brief: Adicet Bio Receives FDA Fast Track Designation For ADI-001 In Lupus Nephritis
Adicet Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Adicet Bio Q1 Basic EPS USD -0.35
Adicet Bio Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Adicet Bio Highlights Preclinical Data Supporting IND Readiness For ADI-270
Brief: Adicet Bio May Offer And Sell Shares Of Common Stock
Adicet Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Adicet Bio Q4 Basic EPS USD -0.69
Adicet Bio Inc expected to post a loss of 69 cents a share - Earnings Preview
Brief: Carlyle Group Reports 4.1% Stake In Adicet Bio As Of January 25- SEC Filing
Brief: RA Capital Management, L.P. Reports 9.99% Passive Stake In Adicet Bio
Brief: Adicet Bio, Inc. Announces Closing Of $98 Million Public Follow-On Offering And Exercise In Full Of The Underwriters’ Option To Purchase Additional Shares